Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Poulin

Showing results (61-70 of 107) with videos related to

Pageof 11
Sort By:
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Update on alefacept safetyDenise Wexler, Gordon Searles, Ian Landells, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|August 31, 2017
Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcomeHermenio Lima, Melinda Gooderham, Jan Dutz, et al.
Journal of Cutaneous Medicine and Surgery|November 22, 2017
Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 InhibitionRobert Bissonnette, Marc Bourcier, Melinda Gooderham, et al.
Acta Dermato-Venereologica|October 18, 2019
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical TrialLyn Guenther, Alison Potts Bleakman, Jamie Weisman, et al.
Journal of Cutaneous Medicine and Surgery|May 4, 2005
Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004Lyn Guenther, Richard G Langley, Neil H Shear, et al.
Journal of Cutaneous Medicine and Surgery|September 17, 2016
Review of Systemic Treatment Options for Adult Atopic DermatitisMelinda Gooderham, Charles W Lynde, Kim Papp, et al.
Journal of Cutaneous Medicine and Surgery|June 23, 2017
Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus DocumentAfsaneh Alavi, Charles Lynde, Raed Alhusayen, et al.
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label studyBruce E Strober, Yves Poulin, Francisco A Kerdel, et al.
Frontiers in Medicine|March 31, 2022
Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-IIStephanie Ghazal, Zainab Ridha, Kathleen D'Aguanno, et al.
Pageof 11

Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Update on alefacept safetyDenise Wexler, Gordon Searles, Ian Landells, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|August 31, 2017
Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcomeHermenio Lima, Melinda Gooderham, Jan Dutz, et al.
Journal of Cutaneous Medicine and Surgery|November 22, 2017
Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 InhibitionRobert Bissonnette, Marc Bourcier, Melinda Gooderham, et al.
Acta Dermato-Venereologica|October 18, 2019
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical TrialLyn Guenther, Alison Potts Bleakman, Jamie Weisman, et al.
Journal of Cutaneous Medicine and Surgery|May 4, 2005
Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004Lyn Guenther, Richard G Langley, Neil H Shear, et al.
Journal of Cutaneous Medicine and Surgery|September 17, 2016
Review of Systemic Treatment Options for Adult Atopic DermatitisMelinda Gooderham, Charles W Lynde, Kim Papp, et al.
Journal of Cutaneous Medicine and Surgery|June 23, 2017
Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus DocumentAfsaneh Alavi, Charles Lynde, Raed Alhusayen, et al.
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label studyBruce E Strober, Yves Poulin, Francisco A Kerdel, et al.
Frontiers in Medicine|March 31, 2022
Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-IIStephanie Ghazal, Zainab Ridha, Kathleen D'Aguanno, et al.
Pageof 11